The new assay captures and enumerates CMMCs from peripheral blood. It has the potential to reduce bone marrow biopsies with a noninvasive method to monitor multiple myeloma evolution and study disease biology.
CMMCs are increased in the peripheral blood of multiple myeloma patients and in patients with two precursor diseases: monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM). Because there is a high degree of correlation between Cellsearch CMMC counts and disease burden, the assay has the potential to offer a standardized method to monitor disease status in clinical trials, the firm said.
Copyright © 2021 LabPulse.com